Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > Significant vision loss in AMD often precedes detectable foveal changes
  • Geographic Atrophy

Significant vision loss in AMD often precedes detectable foveal changes

Kelsey Moroz

In patients with geographic atrophy (GA) due to non-exudative age-related macular degeneration (AMD), significant visual acuity (VA) loss can occur before detectable foveal involvement, according to a study.

The retrospective, longitudinal cohort study included 80 eyes from 60 patients with non-neovascular AMD, observed over an average period of 60 months using blue-light fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT).

Results showed a steady decline in VA, with an average monthly decrease of 0.010 LogMAR. The onset of foveal involvement significantly worsened this decline, leading to an additional loss of 0.15 LogMAR. Rapid VA decline was often detected months before visible foveal damage, particularly in patients with specific FAF patterns and smaller baseline GA lesions.

The researchers concluded that these finding suggests there is an opportunity for early intervention to slow down the progression of visual impairment and underscores the need for personalized treatment strategies based on specific retinal characteristics.

Reference
Cicinelli MV, Barlocci E, Rissotto F, et al. The Discrepancy Between Visual Acuity Decline and Foveal Involvement in Geographic Atrophy. Ophthalmol Retina. 2024;S2468-6530(24)00361-0. doi: 10.1016/j.oret.2024.07.025. Epub ahead of print. PMID: 39121994.

 

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

Share

Related Content

  • Geographic Atrophy

Spotlight on IZERVAY®

  • Geographic Atrophy

Two-year GATHER2 data show sustained GA growth reduction with avacincaptad pegol

  • Conference Roundup

Floretina 2025: study shows reduced treatment burden with EYP-1901 for neovascular AMD

3 Mins Watch
  • Geographic Atrophy

Over half of patients with dry AMD developed advanced disease in long-term analysis

  • Geographic Atrophy

Monthly avacincaptad pegol reduces geographic atrophy lesion growth for up to 3.5 years

  • Anterior Segment

Deep learning algorithm performs similarly to manual grading of GA on an OCT data set

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon